Antisense oligonucleotide treatment for myotonic dystrophy
反义寡核苷酸治疗强直性肌营养不良
基本信息
- 批准号:8658859
- 负责人:
- 金额:$ 77.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2016-09-30
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAffectAnimal ModelAntisense OligonucleotidesBiodistributionCell NucleusCellsCessation of lifeChemicalsChemistryClinicClinicalClinical ProtocolsCollaborationsComplexDefectDevelopmentDevelopment PlansDiseaseDisease ProgressionDoseDrug KineticsEvaluationEventFunctional RNAFunctional disorderGene TargetingGenerationsGenesGeneticGenetic TranscriptionGoalsHumanInheritedInstitutionLeadMacaca fascicularisMedicalMessenger RNAMonkeysMusMuscleMuscular DystrophiesMutationMyocardiumMyotoniaMyotonic DystrophyNeuronsNuclearNucleic Acid HybridizationPatientsPharmaceutical PreparationsPharmacologyPharmacology and ToxicologyPhasePhenotypePilot ProjectsPlant RootsProcessProtein KinaseRNARNA SplicingRNA-Binding ProteinsRattusRegimenRegulationResearch PersonnelRibonuclease HRodentSafetySignal PathwaySkeletal MuscleSmooth MuscleSpecificityStagingSubcutaneous InjectionsSymptomsTherapeuticTherapeutic IndexTissuesToxic effectToxicologyTranscriptTransgenic MiceWild Type Mousebasedisabilitydrug discoveryeffective therapyexperienceimprovedin vivomouse modelmutantpre-clinicalprematureprotein activationpublic health relevanceresponseskeletalstemsubcutaneousuptake
项目摘要
DESCRIPTION (provided by applicant): Myotonic dystrophy type 1 (DM1) is a relatively common form of muscular dystrophy. The genetic basis is an expansion of CTG repeats in the 3' untranslated region of DMPK, a gene encoding a protein kinase expressed in skeletal, cardiac, and smooth muscle, and in neurons. This unusual mutation gives rise to RNA dominance, in which expression of RNA containing an expanded CUG (CUG^"'') repeat leads cell dysfunction. The mutant RNA accumulates in nuclear foci and initiates a complex cascade of downstream events, such as, defects in the regulation of RNA splicing. An attractive therapeutic approach, therefore, is to attack the problem at its root cause, by accelerating the clearance of the toxic RNA. To this end, we are proposing to develop RNase H-active antisense oligonucleotides (ASOs) targeting the mutant human DMPK {mut-hDMPK) mRNA. Previous studies have indicated that biodistribution and activity of ASOs in skeletal and candiac muscle is low. In contrast, we have found that systemically-delivered ASOs are highly active in muscle of wild-type mice, when targeted against a transcript that is retained in the nucleus - presumably because this is the compartment in which RNase H is active. We therefore postulated that CUG-expanded transcripts may also show efficient knockdown in muscle, because they also are retained in the nucleus. Consistent with this idea, subcutaneous administration of ASO for four weeks caused highly effective knockdown of CUG(R)"'' transcripts in muscle, reversal of RNA splicing derangements, and rescue of myotonia in transgenic mice. We seek now to develop optimally-effective, systemically-active ASOs that target mut- hDMPK transcripts for cleavage in skeletal and cardiac muscle. Development plans call for identification of ASOs that are highly active in cells, selection of ASOs that show optimal mut-hDMPK knockdown in transgenic mice, elimination of ASOs that show unacceptable toxicity in rodents and monkeys, and then IND- enabling toxicology/pharmacology studies using GMP-manufactured drug. To accomplish these goals we have formed an academic-commercial collaboration that includes all of the scientific, clinical, regulatory, and manufacturing expertise that is needed to bring a drug treatment for DM1 to the clinic.
描述(由申请人提供):强直性肌营养不良1型(DM1)是一种相对常见的肌营养不良症。遗传基础是DMPK 3‘非翻译区CTG重复序列的扩张,DMPK是一种编码蛋白激酶的基因,在骨骼肌、心肌、平滑肌和神经元中表达。这种不寻常的突变导致RNA占优势,其中含有扩展的CUG(CUG^“‘’)重复序列的RNA表达导致细胞功能障碍。突变的RNA聚集在核焦点中,并启动一系列复杂的下游事件,如RNA剪接调控的缺陷。因此,一个有吸引力的治疗方法是通过加速清除有毒RNA来从根本上解决问题。为此,我们建议开发针对突变的人DMPK(mut-hDMPK)mRNA的RNaseH活性反义寡核苷酸(ASO)。以往的研究表明,ASOS在骨骼肌和心肌中的生物分布和活性都很低。相比之下,我们发现,当针对保留在细胞核中的转录本时,系统传递的ASO在野生型小鼠的肌肉中高度活跃--可能是因为这是RNaseH活跃的隔室。因此,我们推测,CUG扩展的转录本也可能在肌肉中显示有效的敲除,因为它们也保留在细胞核中。与这一想法一致的是,皮下注射ASO四周后,转基因小鼠的CUG(R)‘’转录本被高效地敲除,RNA剪接错乱被逆转,肌强直得到挽救。我们现在寻求开发最有效的、系统活性的ASO,目标是在骨骼肌和心肌中切割MUT-hDMPK转录本。开发计划要求鉴定在细胞中高度活跃的ASO,选择在转基因小鼠中显示最佳mut-hDMPK敲除的ASO,消除对啮齿动物和猴子具有不可接受毒性的ASO,然后使用GMP制造的药物进行IND毒理学/药理学研究。为了实现这些目标,我们已经形成了一个学术-商业合作,其中包括将DM1药物治疗引入临床所需的所有科学、临床、监管和制造专业知识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES A THORNTON其他文献
CHARLES A THORNTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES A THORNTON', 18)}}的其他基金
Therapeutic Modulation of Myotonic Muscular Dystrophy
强直性肌营养不良症的治疗调节
- 批准号:
10222788 - 财政年份:2015
- 资助金额:
$ 77.23万 - 项目类别:
Therapeutic Modulation of Myotonic Muscular Dystrophy
强直性肌营养不良症的治疗调节
- 批准号:
9133482 - 财政年份:2015
- 资助金额:
$ 77.23万 - 项目类别:
Biomarkers of therapeutic response in myotonic dystrophy
强直性肌营养不良治疗反应的生物标志物
- 批准号:
8952034 - 财政年份:2015
- 资助金额:
$ 77.23万 - 项目类别:
Therapeutic Modulation of Myotonic Muscular Dystrophy
强直性肌营养不良症的治疗调节
- 批准号:
9005275 - 财政年份:2015
- 资助金额:
$ 77.23万 - 项目类别:
Biomarkers of therapeutic response in myotonic dystrophy
强直性肌营养不良治疗反应的生物标志物
- 批准号:
9098817 - 财政年份:2015
- 资助金额:
$ 77.23万 - 项目类别:
Therapeutic Modulation of Myotonic Muscular Dystrophy
强直性肌营养不良症的治疗调节
- 批准号:
9301054 - 财政年份:2015
- 资助金额:
$ 77.23万 - 项目类别:
Therapeutic Modulation of Myotonic Muscular Dystrophy
强直性肌营养不良症的治疗调节
- 批准号:
9984584 - 财政年份:2015
- 资助金额:
$ 77.23万 - 项目类别:
Antisense oligonucleotide treatment for myotonic dystrophy
反义寡核苷酸治疗强直性肌营养不良
- 批准号:
8467066 - 财政年份:2011
- 资助金额:
$ 77.23万 - 项目类别:
Antisense oligonucleotide treatment for myotonic dystrophy
反义寡核苷酸治疗强直性肌营养不良
- 批准号:
8241912 - 财政年份:2011
- 资助金额:
$ 77.23万 - 项目类别:
Antisense oligonucleotide treatment for myotonic dystrophy
反义寡核苷酸治疗强直性肌营养不良
- 批准号:
8033858 - 财政年份:2011
- 资助金额:
$ 77.23万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 77.23万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 77.23万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 77.23万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 77.23万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 77.23万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 77.23万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 77.23万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 77.23万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 77.23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 77.23万 - 项目类别: